RSV Prevention Tied to Lower Infant Acute Care Use - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

RSV Prevention Tied to Lower Infant Acute Care Use

Data suggest fewer respiratory syncytial virus–associated hospitalizations and emergency department visits among the youngest infants during the second season of routine prevention product use.

  • By

  • Andrea Surnit

  • May 5, 2026

  • 5 min

Share

  • 1

    A Washington state study found a 43% decrease in RSV-associated hospitalizations and ED visits among infants under 7 months during the second year of nirsevimab use.

  • 2

    The study analyzed 16,775 RSV-related encounters, revealing a significant decline in rates from 6.1 to 2.6 per 100 population between the 2022-2023 and 2024-2025 seasons.

  • 3

    Immunization coverage for infants increased, with approximately 39% immunized in the first season and coverage doubling in the second season, contributing to the observed impact.

  • 4

    The estimated population impact varied by county, with decreases ranging from 15.5% to 57.7%, and was greater among White infants compared to Native Hawaiian or Other Pacific Islander infants.

  • 5

    Clesrovimab, a new monoclonal antibody, was approved in June 2025, offering a potential expansion of RSV prevention strategies with easier storage and dosing.

Original Source(s)

RSV Prevention Tied to Lower Infant Acute Care Use

  • by Andrea Surnit

  • May 5, 2026

Related Content

Does Sedative Choice Shape Later Cognition?

Researchers examined long-term cognitive outcomes among children who received ICU sedation for acute respiratory failure.

CT Use May Add to Future Cancer Burden

Researchers projected approximately 103,000 future cancers associated with computed tomography examinations performed in the US in 2023.

Youth Vaping Is "Predictable" by Design

Product engineering, not individual choice, is driving adolescent nicotine dependence, researchers argue.